Comparison

Cagrilintide vs. Lixisenatide

Two peptides side-by-side — identity, evidence base, legal status and known adverse events.

Identity

Mechanism of action

Cagrilintide

Cagrilintide binds amylin receptors (AMY1, AMY3, formed by the calcitonin receptor plus RAMP proteins). Activation delays gastric emptying, inhibits postprandial glucagon secretion and modulates central satiety signalling via area postrema neurons. An acyl modification enables albumin binding and thereby weekly dosing.

Lixisenatide

Lixisenatide is a 44-amino-acid peptide based on exendin-4 (see exenatide) with six additional lysine residues at the C-terminus. This modification increases stability against DPP-4 degradation. The short half-life (~3 hours) and plasma peak around mealtime explain the predominantly prandial effect — stronger postprandial glucose action, weaker fasting glucose effect than weekly GLP-1 RAs.

Evidence base

Highest evidence

Human RCT

Studies

of which in humans

Effects recorded

Open conflicts

Documented adverse events

Legal status

Country	Cagrilintide	Lixisenatide
Germany	Unapproved	Prescription
DK	Unapproved	—
JP	—	Prescription
United States	Unapproved	Unapproved

Full entries

Frequently asked questions

What is the difference between Cagrilintide and Lixisenatide?: Cagrilintide is classified as "Metabolic", while Lixisenatide is classified as "Metabolic". Cagrilintide: Synthetic long-acting amylin analog being developed in combination with semaglutide (CagriSema). Phase 3 trials for obesity and type 2 diabetes are ongoing. No marketing approval yet. Lixisenatide: Synthetic exendin-4 analog with a C-terminal lysine extension. Prandial GLP-1 RA focused on postprandial glucose. FDA-approved 2016 as Adlyxin; EMA-approved 2013 as Lyxumia. Sanofi discontinued US distribution in 2023. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
Which peptide is better supported by science, Cagrilintide or Lixisenatide?: The highest available evidence level is "Human RCT" for Cagrilintide and "Human RCT" for Lixisenatide. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
What is the legal status of Cagrilintide and Lixisenatide in Germany and the United States?: Germany: Cagrilintide — Unapproved, Lixisenatide — Prescription. United States: Cagrilintide — Unapproved, Lixisenatide — Unapproved. These are factual summaries with source and review date on the individual pages.

Country

Cagrilintide

Lixisenatide

Germany

Unapproved

Prescription

Unapproved

—

Prescription

United States

Unapproved

Frequently asked questions

What is the difference between Cagrilintide and Lixisenatide?

Cagrilintide is classified as "Metabolic", while Lixisenatide is classified as "Metabolic". Cagrilintide: Synthetic long-acting amylin analog being developed in combination with semaglutide (CagriSema). Phase 3 trials for obesity and type 2 diabetes are ongoing. No marketing approval yet. Lixisenatide: Synthetic exendin-4 analog with a C-terminal lysine extension. Prandial GLP-1 RA focused on postprandial glucose. FDA-approved 2016 as Adlyxin; EMA-approved 2013 as Lyxumia. Sanofi discontinued US distribution in 2023. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.

Which peptide is better supported by science, Cagrilintide or Lixisenatide?

The highest available evidence level is "Human RCT" for Cagrilintide and "Human RCT" for Lixisenatide. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.

What is the legal status of Cagrilintide and Lixisenatide in Germany and the United States?

Germany: Cagrilintide — Unapproved, Lixisenatide — Prescription. United States: Cagrilintide — Unapproved, Lixisenatide — Unapproved. These are factual summaries with source and review date on the individual pages.